Sterile fill finish news, resources and insights
Explore technical content, expert perspectives and practical guidance covering sterile fill finish manufacturing, technology transfer, contamination control, quality and more.
Filter
Why successful technology transfers can start by slowing down
Technology transfer programs often face pressure to move quickly, but rushing through the early stages can lead to costly execution delays when teams start before internal alignment is complete. By slowing down, teams can streamline the process, ensure alignment from the start, and challenge assumptions before the transfer begins. In other words, slow is smooth; […]
Read more
Bridging the gap between upstream precision and downstream excellence in aseptic fill finish
The pressure to bring complex therapies, including biologics and glucagon-like peptide-1 (GLP-1) agonists, to market quickly has placed a significant strain on commercial production networks. As drug developers respond to growing demand for these therapies, the transition from bench top discovery to commercial aseptic fill finish volumes can happen quickly. But, when upstream processing scales […]
Read more
Turning media fill data into stronger aseptic control in an Annex 1 era
Media fills provide an important demonstration of aseptic process performance, as the information gathered during a simulation gives manufacturers a stronger understanding of how the process behaves over time. As companies must now translate their media fill processes to meet Annex 1 expectations, the way this information is reviewed can provide valuable insight into aseptic […]
Read more
Rethinking media fill strategy in the Annex 1 era
Media fills play a central role in aseptic process validation, providing a practical demonstration that a manufacturing process can be carried out without introducing microbial contamination. However, under the revised EU GMP Annex 1 guidance, the focus has shifted, and an acceptable final incubation result is no longer sufficient on its own. Now, media fills […]
Read more
What’s behind the decisions shaping successful fill finish programs?
Advanced equipment and available cleanroom capacity are important considerations when choosing a sterile fill finish CDMO partner, but they only form part of the decision. As a drug program nears cGMP manufacturing, careful consideration of technical, quality, and operational readiness is essential, as it shapes how confidently a program can progress. These considerations take place […]
Read more
Building sterile injectable manufacturing capacity for growing GLP-1 demand
Glucagon-like peptide-1 (GLP-1) receptor agonists are being prescribed more frequently, increasing pressure on sterile injectable manufacturing networks. To effectively serve expanding patient populations, developers must increase output while maintaining product quality and regulatory compliance without disrupting the supply of other therapies. Meeting the growing GLP-1 demand requires manufacturing models that can manage high-volume programs alongside […]
Read more
Meeting the challenges of fill finish manufacturing
How flexible infrastructure and early manufacturing expertise can help drug developers respond to changing demand With rising demand for glucagon-like peptide-1 (GLP-1) medicines, continued progress in biologics and the expansion of self-administered treatments, new expectations are being placed on sterile fill finish operations. Manufacturers must accommodate different container formats and production volumes while maintaining consistent […]
Read more
Parenteral precision: Upstream formulation handling before sterile fill finish
Parenteral precision is a blog series exploring the controls, technologies and design decisions that shape modern parenteral manufacturing. Each article looks at one capability through a practical lens: what it is, how it works, who it supports and why it matters. In our first blog, we explored how sterile fill finish operations are designed around […]
Read more
Delivering tomorrow’s injectables, today
Injectable therapies are entering a new phase of complexity. Biologics, personalized medicines and combination products are increasing demand for delivery systems that must adapt to more diverse formats and patient needs. Expectations around speed and compliance also continue to rise across the development lifecycle, placing greater pressure on how these systems are designed and scaled. […]
Read more